Skip to main content
Fig. 1 | Journal for ImmunoTherapy of Cancer

Fig. 1

From: Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody

Fig. 1

Summary of the patient’s hospital stay including changes in laboratory results and treatment. Dotted lines indicate grade 3 adverse events according to the Common Terminology Criteria for Adverse Events, Version 4. AST indicates aspartate transaminase; ALT, alanine transaminase; CK-MB, creatinine kinase isoenzyme MB; CK, creatinine kinase; ULN, upper limit of normal; AE, adverse event; IPI, ipilimumab; NIVO, nivolumab; Trach, tracheostomy; IVIG, intravenous immunoglobulin

Back to article page